• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H2 2012 Product Image

Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H2 2012

  • Published: July 2012
  • 59 pages
  • Global Markets Direct

Vancomycin-Resistant Enterococcus Faecium Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H2 2012', provides an overview of the Vancomycin-Resistant Enterococcus Faecium Infections therapeutic pipeline. This report provides information on the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections. 'Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated READ MORE >

2
List of Tables 4
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Vancomycin-Resistant Enterococcus Faecium Infections Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Vancomycin-Resistant Enterococcus Faecium Infections 8
Vancomycin-Resistant Enterococcus Faecium Infections Therapeutics under Development by Companies 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Discovery and Pre-Clinical Stage Products 15
Comparative Analysis 15
Vancomycin-Resistant Enterococcus Faecium Infections Therapeutics – Products under Development by Companies 16
Companies Involved in Vancomycin-Resistant Enterococcus Faecium Infections Therapeutics Development 17
Ceragenix Pharmaceuticals, Inc. 17
Piramal Healthcare Limited 18
Wockhardt Limited 19
Paratek Pharmaceuticals, Inc. 20
Immtech Pharmaceuticals, Inc. 21
Lorus Therapeutics Inc 22
Oragenics, Inc. 23
MerLion Pharmaceuticals Pte Ltd 24
MicuRx Pharmaceuticals, Inc. 25
Trius Therapeutics, Inc. 26
Vancomycin-Resistant Enterococcus Faecium Infections – Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
LOR-220 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Omadacycline - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Antibiotic Program - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
MU1140 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Lipopeptide Programme - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
PM181104 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Tedizolid Phosphate - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Lipopeptide Program - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
MRX-I - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
CSA-13 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
WCK 4086 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
MRX-II - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
SLP0905 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
SLP0904 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Vancomycin-Resistant Enterococcus Faecium Infections Therapeutics – Drug Profile Updates 49
Vancomycin-Resistant Enterococcus Faecium Infections Therapeutics - Dormant Products 54
Vancomycin-Resistant Enterococcus Faecium Infections – Product Development Milestones 55
Featured News & Press Releases 55
May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent 55
Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I 55
Mar 27, 2012: Lorus Therapeutics Announces Positive Results From Small Molecule Antimicrobial Program 56
Oct 21, 2010: Lorus Therapeutics Announces Allowance Of US Patent For Lead Antimicrobial Small Molecule 56
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59

List of Tables
Number of Products Under Development for Vancomycin-Resistant Enterococcus Faecium Infections, H2 2012 8
Products under Development for Vancomycin-Resistant Enterococcus Faecium Infections – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Ceragenix Pharmaceuticals, Inc., H2 2012 17
Piramal Healthcare Limited, H2 2012 18
Wockhardt Limited, H2 2012 19
Paratek Pharmaceuticals, Inc., H2 2012 20
Immtech Pharmaceuticals, Inc., H2 2012 21
Lorus Therapeutics Inc, H2 2012 22
Oragenics, Inc., H2 2012 23
MerLion Pharmaceuticals Pte Ltd, H2 2012 24
MicuRx Pharmaceuticals, Inc., H2 2012 25
Trius Therapeutics, Inc., H2 2012 26
Assessment by Monotherapy Products, H2 2012 27
Assessment by Stage and Route of Administration, H2 2012 29
Assessment by Stage and Molecule Type, H2 2012 31
Vancomycin-Resistant Enterococcus Faecium Infections Therapeutics – Drug Profile Updates 49
Vancomycin-Resistant Enterococcus Faecium Infections Therapeutics – Dormant Products 54

List of Figures
Number of Products under Development for Vancomycin-Resistant Enterococcus Faecium Infections, H2 2012 8
Products under Development for Vancomycin-Resistant Enterococcus Faecium Infections – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Discovery and Pre-Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 27
Assessment by Route of Administration, H2 2012 28
Assessment by Stage and Route of Administration, H2 2012 29
Assessment by Molecule Type, H2 2012 30
Assessment by Stage and Molecule Type, H2 2012 31

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos